Phase I study of gemcitabine, docetaxel and imatinib in refractory and relapsed solid tumors

PURPOSE: In a phase I study, the combination of gemcitabine and imatinib was well tolerated with broad anticancer activity. This phase I trial evaluated the triplet of docetaxel, gemcitabine and imatinib. EXPERIMENTAL DESIGN: Imatinib was administered at 400 mg daily on days 1–5, 8–12 and 15–19. Gem...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Invest New Drugs
Egile Nagusiak: Saraiya, Biren, Chugh, Rashmi, Karantza, Vassiliki, Mehnert, Janice, Moss, Rebecca A., Savkina, Nelli, Stein, Mark N., Baker, Laurence H., Chenevert, Thomas, Poplin, Elizabeth A.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2010
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5300057/
https://ncbi.nlm.nih.gov/pubmed/20697775
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-010-9504-5
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak